European Journal of Cancer
Volume 41, Issue 14 , Pages 2086-2092, September 2005

Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study

Research Institute and Hospital, National Cancer Center, 809, Madu-dong, Ilsan, Goyang, Gyeonggi, Korea

Received 20 January 2005; received in revised form 17 May 2005; accepted 18 May 2005.

Abstract 

We evaluated the accuracy of FDG-PET in diagnosing metastatic para-aortic and pelvic lymph nodes in patients with cervical cancer by comparing this noninvasive imaging technique with surgicopathologic results. We performed FDG-PET in 54 patients with cervical cancer at FIGO stages IB–IVA who were about to undergo lymphadenectomy. For region-specific comparisons, we divided the nodes into eight regions (four on each side: para-aortic, common iliac, external iliac, and internal iliac/obturator). Histological examination revealed metastases in 15 (28%) of the patients, with region-specific analysis identifying 37 (8.6%) metastases in 432 regions. The region-specific findings of FDG-PET exhibited a sensitivity of 38% and a positive predictive value (PPV) of 56%. The sensitivity increased to 52% and 65% when we restricted the pathologic criterion for metastases to tumour-invasion diameters of >5 and >10mm, respectively. These results indicate that FDG-PET exhibited low sensitivity and PPV (especially for microscopic metastases) and hence cannot replace surgical staging, although it might still be useful for detecting metastases in patients with clinical conditions that make surgical staging inappropriate.

Keywords: Cervical cancer, Positron emission tomography, FDG-PET, Lymph node staging, Surgical staging

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)00554-X

doi:10.1016/j.ejca.2005.05.013

European Journal of Cancer
Volume 41, Issue 14 , Pages 2086-2092, September 2005